A 62-year-old woman with seropositive rheumatoid arthritis on methotrexate 20 mg/week has DAS28-CRP of 4.9 after 6 months. Anti-CCP titre is > 3× ULN and she has erosions on X-ray. Per EULAR 2022 and ACR 2021 guidelines, the most appropriate next step is:
- A Add leflunomide to form triple DMARD therapy before escalating to biologics
- B Switch to a TNF inhibitor as first biologic DMARD ✓
- C Add a JAK inhibitor (tofacitinib) as the preferred first-line biologic-free escalation
- D Add sulfasalazine + hydroxychloroquine (O'Dell triple therapy) as next step before biologics
Explanation
EULAR 2022 recommends that when the treatment target is not achieved after 3–6 months on conventional synthetic DMARDs (csDMARD) in patients with poor prognostic factors (high anti-CCP, erosive disease, high disease activity), escalation to a biologic DMARD or targeted synthetic DMARD should occur promptly. TNF inhibitors are the preferred first biologic class with the longest safety record. JAK inhibitors carry additional cardiovascular and malignancy warnings (ORAL Surveillance data) limiting their use to patients who have failed biologics or have contraindications to biologics per updated ACR/EULAR guidance. Triple csDMARD therapy is an option but not preferred given erosive disease and high anti-CCP.
Reference: Harrison's Principles of Internal Medicine, 21st ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.